KOSDAQMachinery068330

ilShinbiobase

₩975▲ 0.52%2026-11-18 close
Market Cap
₩43.1B
Turnover
₩40,048,272
Volume
40K
Shares out.
44.2M
PER
8.9×
PBR
0.6×
EPS
₩110
Dividend Yield
1.02%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩10 per share · Prices as of the 2026-11-18 close

01

Report overview

Freeze-Dryer Maker Between Profit Recovery and Listing Standards

ilShinbiobase makes freeze dryers and ultra-low temperature freezers. Operating profit recovered in 2025, but earnings fell sharply in the third quarter of 2026 while the share price sits in a range that drew a listing-standard warning.

  1. 1

    Operating profit rose 101.0% year on year to KRW 4.55 billion in 2025, with an operating margin of 31.3%.

  2. 2

    Third-quarter 2026 operating profit was KRW 781 million, down 59.0% year on year, and profit attributable to controlling shareholders fell 74.1% to KRW 499 million.

  3. 3

    Two single supply contracts disclosed in January 2026, worth KRW 4.29 billion and KRW 2.25 billion, equaled 39.7% and 20.8% of 2024 revenue, showing how a few orders can drive quarterly results.

  4. 4

    Total equity stood at KRW 64.8 billion at the end of 2025 against total liabilities of KRW 3.79 billion, a light debt load.

  5. 5

    An August 11, 2026 exchange notice flagged the stock for possible administrative-issue designation because its share price was below 1,000 won, making listing maintenance a separate variable.

02

Business structure

ilShinbiobase is a bioequipment specialist founded in 1988 that mainly makes freeze dryers and ultra-low temperature freezers. Its line runs from small laboratory models to large plant-scale freeze dryers for pharmaceutical and food industry use, and it also produces blood bank refrigerators, ice makers and shakers.

A business-segment tally on a Korean recruitment site shows Lyoph-Pride series freeze dryers making up a majority of the mix. Its customers include pharmaceutical companies, vaccine and biologics makers, and producers of probiotics and health foods.

In January 2026, a supply contract for an aseptic-formulation automated freeze dryer worth KRW 4.29 billion and a separate freeze-dryer contract worth KRW 2.25 billion were disclosed.

Both amounts equal 39.7% and 20.8% of 2024 revenue of KRW 10.8 billion, which shows that single orders carry a large weight in this business. According to company profile material, the Dongducheon plant has capacity for more than 200 freeze dryers a year.

Exports are expanding to markets including Austria, Chile and Malaysia, and the company has shifted to direct sales by country to strengthen local sales and technical support.

Competition comes from overseas freeze-dryer makers as well as domestic import-substitution demand, and precise control, energy efficiency and temperature stability are cited as differentiators.

A patented shelf structure that keeps temperature variation within plus or minus 1 degree Celsius is also presented as a technical basis.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.9B₩1.9B39.2%
2025Q4₩4.2B₩1.1B25.4%
2026Q1₩2.5B₩500M18.0%
2026Q2₩4.2B₩1.5B36.6%
2026Q3₩3.7B₩800M21.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩20.4B₩5.1B₩3.8B25.2%7.1%8.6%
2023₩16.4B₩6.2B₩6.2B37.8%10.9%6.2%
2024₩10.8B₩2.3B₩3.8B20.9%6.3%5.8%
2025₩14.5B₩4.5B₩4.8B31.3%7.4%5.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On DART periodic-report figures, annual revenue went from KRW 20.4 billion in 2022 to KRW 16.4 billion in 2023 (down 19.6% year on year) and KRW 10.8 billion in 2024 (down 34.2%), before rising to KRW 14.5 billion in 2025 (up 34.3%). Across 2022 to 2025, 2022 was the largest year and 2024 the smallest.

Operating profit moved from KRW 5.14 billion in 2022 to KRW 6.21 billion in 2023 (up 20.9%), fell to KRW 2.26 billion in 2024 (down 63.6%), and recovered to KRW 4.55 billion in 2025 (up 101.0%).

Operating margins were 25.2%, 37.8%, 20.9% and 31.3% for 2022 through 2025, so the weakest margin came in the lowest-revenue year. This pattern suggests that margins swing widely with order volume, since fixed costs are spread over a smaller or larger revenue base.

Profit attributable to controlling shareholders was KRW 3.82 billion in 2022, KRW 6.23 billion in 2023 (up 63.4%), KRW 3.81 billion in 2024 (down 38.8%) and KRW 4.79 billion in 2025 (up 25.8%). Operating cash flow of KRW 5.27 billion in 2025 exceeded that attributable profit.

Quarterly, third-quarter 2025 revenue was KRW 4.87 billion with operating profit of KRW 1.91 billion; fourth-quarter revenue slipped 13.0% to KRW 4.23 billion and operating profit to KRW 1.08 billion. The first quarter of 2026 was the low point, with revenue of KRW 2.52 billion and operating profit of KRW 454 million.

The second quarter rebounded to revenue of KRW 4.17 billion (up 65.7% quarter on quarter) and operating profit of KRW 1.53 billion.

Third-quarter 2026 revenue of KRW 3.66 billion (down 24.7% year on year), operating profit of KRW 781 million (down 59.0%) and attributable profit of KRW 499 million (down 74.1%) reversed that recovery, and attributable profit over the last four quarters totaled KRW 4.59 billion.

The disclosed figures alone do not pin down the direct cause of the quarterly swings, though the timing of revenue recognition on large orders may have played a role.

05

Industry analysis

The global freeze-dryer market is growing on long-term preservation demand for high-value medicines such as biopharmaceuticals, vaccines and cell therapies. Valueline projects that the market will grow from about USD 2 billion in 2024 to USD 4.5 billion in 2033.

The same profile describes ilShinbiobase as leading import substitution in Korea. A summary site on disclosures attributed the 2025 revenue increase partly to a partial recovery in biopharma industry conditions.

The company's revenue bottomed in 2024 and rebounded in 2025, which fits the view that customers' equipment investment timing drives order timing. Where the company sits in the cycle is hard to call, as the 2025 recovery and the slowdown in the third quarter of 2026 appeared together after the 2024 low.

Competition comes from overseas freeze-dryer makers as well as domestic players. ilShinbiobase has widened its lineup from laboratory units to plant-scale equipment, which spreads its customer base.

In June 2026, the company was reported to be taking on the development of intelligent sealed freeze-drying equipment within a KRW 26.3 billion national research project led by a Chonbuk National University team on a DCS biopharma platform, which broadens its demand base toward research institutions and government projects.

06

Outlook

The disclosures do not include a company target for annual revenue or profit. Instead, orders and projects confirmed during 2026 are the starting point for future results.

In January 2026, a KRW 4.29 billion automated freeze-dryer contract for aseptic formulation and a KRW 2.25 billion freeze-dryer contract were disclosed.

In June 2026, ilShinbiobase was reported to be taking on the development of intelligent sealed freeze-drying equipment within a KRW 26.3 billion national project led by a Chonbuk National University team. The KRW 26.3 billion is the total project size, not the company's share.

On the product side, the company is widening its customer range through automated aseptic-formulation units and large plant-scale equipment. The failure of the second-quarter 2026 rebound to carry into the third quarter suggests that the timing of large orders shows up directly in quarterly results.

Reports say the largest shareholder group's stake rose to 32.15% after director Hong Jung-ki bought shares on the market in June 2026. Because a warning notice was issued on August 11, 2026, managing the share price and listing requirements remains a near-term task.

The next checkpoint is how the operating margin in the 2026 annual business report compares with the 31.3% recorded in 2025.

07

Valuation

PER
8.9×
PBR
0.6×
ROE
7.0%
EPS
₩110
BPS
₩1,622
Dividend per share
₩10

Valuation reads more clearly when the earnings basis and the net-asset basis are viewed separately. Market capitalization is below total equity of KRW 64.8 billion at the end of 2025, so the stock trades at a level below its net assets.

On a price-to-book basis, the stock sits on the lower side of net assets, and the gap between asset value and share price is the starting point for this assessment.

On an earnings basis, profit attributable to controlling shareholders over the last four quarters totaled KRW 4.59 billion, and because third-quarter 2026 earnings fell sharply, the earnings multiple at the same share price rises.

Attributable profit peaked at KRW 6.23 billion in 2023, the largest year across 2022 to 2025, so how far current earnings sit below that peak is a central question. A cash and in-kind dividend decision was disclosed on February 13, 2026, and the dividend yield moves with the share price.

The share price remaining below the 1,000-won threshold adds a separate variable to market assessment, alongside the administrative-issue warning. With the largest shareholder group holding 32.15%, the limited free float is another factor in trading dynamics.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Financial room: large net assets and low debt

Total equity at the end of 2025 was KRW 64.8 billion, all of it attributable to controlling shareholders, against total liabilities of KRW 3.79 billion. The debt-to-equity ratio fell from 8.6% in 2022 to 5.8% in 2025. Market capitalization sits below total equity, which places the stock on the lower side of net assets.

Profit recovery and cash generation in 2025

Operating profit rose 101.0% to KRW 4.55 billion in 2025, with an operating margin of 31.3%. Operating cash flow of KRW 5.27 billion exceeded the KRW 4.79 billion attributable net profit for the same year. The second quarter of 2026 showed a recovery signal, with operating profit of KRW 1.53 billion.

Technology certifications and overseas expansion

The company is reported to hold US ETL and European CE certifications, and it holds patents on freeze-dryer technology. Exports are growing to markets including Austria, Chile and Malaysia, and the company is shifting to direct sales by country.

In June 2026, it was reported to be taking on sealed freeze-drying equipment development in a KRW 26.3 billion national project.

09

Bear factors

Sharp earnings drop in the third quarter of 2026

Third-quarter 2026 revenue of KRW 3.66 billion fell 24.7% year on year. Operating profit of KRW 781 million dropped 59.0%, and profit attributable to controlling shareholders of KRW 499 million fell 74.1%.

The second-quarter rebound did not carry into the third quarter, leaving the direction of quarterly profit unclear.

Reliance on single contracts and a history of revenue decline

The KRW 4.29 billion contract disclosed in January 2026 equaled 39.7% of 2024 revenue of KRW 10.8 billion, and the KRW 2.25 billion contract equaled 20.8%. Revenue fell from KRW 20.4 billion in 2022 to KRW 10.8 billion in 2024, which shows vulnerability to gaps in orders.

Risk of administrative-issue designation

On August 11, 2026, the KOSDAQ market division issued a notice flagging the stock for possible administrative-issue designation because its price was below 1,000 won. Reports said 36 stocks were designated as administrative issues on August 12, 2026, when the tightened delisting standards first applied. If the share price does not return above the threshold, maintaining the listing becomes an added burden.

10

Risk factors

Order volatility

Because single contract sizes drive quarterly revenue, a mismatch in the timing of large orders can cause sharp swings in quarterly results. Revenue of KRW 2.52 billion in the first quarter of 2026 rose 65.7% quarter on quarter to KRW 4.17 billion in the second quarter, then fell to KRW 3.66 billion in the third. Order flow also depends on when customers invest in equipment.

Listing-maintenance requirements

If the share price stays below 1,000 won, further exchange warnings may follow. Reports describe the tightened requirements as targeting stocks under 1,000 won and companies that fail to maintain a certain level of market capitalization. A larger listing-maintenance problem could weigh directly on the share price and trading conditions.

Ownership concentration and free float

The largest shareholder group's stake rose to 32.15%, and CEO Hong Sung-dae held 29.63% as of May 18, 2026. Concentrated holdings leave a limited free float, which can increase trading volatility. Director share purchases show a change in holdings but do not by themselves indicate the direction of the share price.

11

What to watch next

  1. Around February 2027 (expected)

    Preliminary full-year 2026 results. The timing is estimated from the February 13, 2026 disclosure of the 2025 annual change. The key question is how 2026 operating profit compares with KRW 4.55 billion in 2025.

  2. Around March 2027 (expected)

    Filing of the 2026 annual business report and the full-year operating margin. The timing is estimated from the March 19, 2026 filing of the previous annual report. The checkpoints are the change from the 31.3% margin in 2025 and the causes of quarterly revenue swings.

  3. Ongoing, at exchange disclosure dates

    Single-supply contract disclosures and their size. As with the two January 2026 contracts, a large contract relative to prior-year revenue offers a clue to the next quarter's revenue flow.

  4. Ongoing, at exchange disclosure dates

    Whether the stock is designated as an administrative issue and whether the share price recovers above the 1,000-won threshold. The check follows the warning notice of August 11, 2026.

  5. During the project period from June 2026

    Progress on the intelligent sealed freeze-drying equipment under the Chonbuk National University project and its commercialization schedule. This shows when project results could start to feed into revenue.

12

Overall view

ilShinbiobase makes freeze dryers and ultra-low temperature freezers. Revenue fell from KRW 20.4 billion in 2022 to KRW 10.8 billion in 2024 and recovered to KRW 14.5 billion in 2025. Operating profit of KRW 4.55 billion and an operating margin of 31.3% in 2025 show that earnings capacity recovered.

On the balance sheet, total equity of KRW 64.8 billion and total liabilities of KRW 3.79 billion at the end of 2025 indicate a light debt load.

On the other side, third-quarter 2026 revenue of KRW 3.66 billion, operating profit of KRW 781 million and attributable profit of KRW 499 million all fell sharply year on year, so the direction of quarterly profit is not yet settled.

Because revenue leans heavily on single contracts, the timing of large orders drives earnings swings. The share price sitting in the sub-1,000-won range, which led to an August 2026 warning notice, shows that listing requirements are a separate variable.

Strengths include net asset size, the 2025 earnings recovery, export growth and participation in a national project. Weaknesses include the third-quarter 2026 earnings decline, order concentration and listing-maintenance requirements.

The next checkpoints are the full-year operating margin in the 2026 annual business report and preliminary full-year results in early 2027, while administrative-issue designation can be checked through exchange disclosures as they occur.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. jobkorea.co.kr
  2. k5.co.kr
  3. app.rndcircle.io
  4. goinsider.kr
  5. saramin.co.kr
  6. investing.com
  7. valueline.co.kr
  8. anewsa.com
  9. alphasquare.co.kr
  10. datatooza.com
  11. m.irgo.co.kr
  12. bizmetric.co.kr
  13. alphasquare.co.kr
  14. koreadividend.kr
  15. judal.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis